# N4 Pharma testing to generate dose response curve for BCL-2 studies

- Link: https://www.directorstalkinterviews.com/n4-pharma-testing-to-generate-dose-response-curve-for-bcl-2-studies/4121116527
- Published: 2023-04-25T07:22:24+01:00
- Author: Jacob Brown

**N4 Pharma Plc** (LON:N4P), the specialist pharmaceutical company developing Nuvec
®, a novel delivery system for cancer treatments and vaccines, has provided a further
update on its ongoing _in vitro_ siRNA research work.

_BCL-2 assay has been established_

Further to the announcement on 18 April 2023, the Company has now completed work
on establishing assays to measure how Nuvec® loaded with BCL-2 siRNA can silence
expression of the BCL-2 protein. BCL-2 is a form of protein that regulates cell 
death in healthy cells however aberrant expression can facilitate tumour development
and resistance to cancer therapy.

_Testing underway to generate dose response curve for BCL-2 studies_

This means that the Company can now proceed to generate a dose response curve for
knockdown of BCL-2 expression to compliment the one already generated for EGFR (
epidermal growth factor receptor). EGFR is found on the surface of some normal cells
and is involved in cell growth. It may also be found at high levels on some types
of cancer cells, which causes these cells to grow and divide.

_In vitro studies indicate similar inhibition profile to two commercial therapies_

Further _in vitro_ studies have demonstrated that the maximum inhibition of cell
growth by SiRNA to either EGFR or BCL-2 loaded on Nuvec® was comparable to that 
produced by two commercially available small molecule drugs, Gefitinib for EGFR 
and Venetoclax for BCL-2.

Gefitinib: (sold in Europe and Asia) is a type of targeted small molecule cancer
drug called a tyrosine kinase inhibitor (TKI). Tyrosine kinases are proteins that
send signals telling cancer cells to grow. Gefitinib blocks these signals. For Gefitinib
to work the cancer cells need to have receptors for EGFR.

Venetoclax: sold under the brand names Venclexta and Venclyxto, is a type of targeted
therapy drug called a BCL-2 inhibitor (blocker)used to treat adults with chronic
lymphocytic leukaemia, small lymphocytic lymphoma, or acute myeloid leukaemia. Some
leukaemia or cancer cells make too much of the BCL-2 protein.

_Next steps_

Further work is planned to assess the minimal loading of siRNA on Nuvec® to achieve
comparable inhibition to the two commercially available drugs. The next step in 
the _in vitro research work_ is to undertake a full dose response curve study for
siRNA loaded Nuvec® and compare to the dose response curve for Gefitinib and Venetoclax.

> **Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:**
> “We are very pleased with these _in vitro_ results for Nuvec® loaded with EGFR
> and BCL-2, which show that the first investigated dose produces comparable cellular
> apoptosis to two commercially available products.
> “We also now have the assay established to complete the dose response expression
> work for BCL-2, but we already know that BCL-2 must be expressed, as the cell 
> apoptosis work has shown that it knocks down the gene to produce cell death.”

Share on:
